Effect of Nevirapine Toxicity on Choice of Perinatal HIV Prevention Strategies

Dados Bibliográficos

ID11026799
AutoresJeffrey S A Stringer (0000-0002-9590-7216, Jeffrey S. A. Stringer is with the Center for Research in Women's Health, University of Alabama at Birmingham, and the Center for Infectious Disease Research in Zambia, Lusaka, Zambia. Dwight J. Rouse, Robert L. Goldenberg, and Sten H. Vermund are with the Center for Research in Women's Health, University of Alabama at Birmingham. Moses Sinkala is with the Lusaka District Health Board, Zambian Ministry of Health, Lusaka.), Moses Sinkala (0009-0006-6158-4689, Jeffrey S. A. Stringer is with the Center for Research in Women's Health, University of Alabama at Birmingham, and the Center for Infectious Disease Research in Zambia, Lusaka, Zambia. Dwight J. Rouse, Robert L. Goldenberg, and Sten H. Vermund are with the Center for Research in Women's Health, University of Alabama at Birmingham. Moses Sinkala is with the Lusaka District Health Board, Zambian Ministry of Health, Lusaka.), Dwight J Rouse (0000-0002-9336-9688, Jeffrey S. A. Stringer is with the Center for Research in Women's Health, University of Alabama at Birmingham, and the Center for Infectious Disease Research in Zambia, Lusaka, Zambia. Dwight J. Rouse, Robert L. Goldenberg, and Sten H. Vermund are with the Center for Research in Women's Health, University of Alabama at Birmingham. Moses Sinkala is with the Lusaka District Health Board, Zambian Ministry of Health, Lusaka.), Robert L Goldenberg (0000-0002-1283-8340, Jeffrey S. A. Stringer is with the Center for Research in Women's Health, University of Alabama at Birmingham, and the Center for Infectious Disease Research in Zambia, Lusaka, Zambia. Dwight J. Rouse, Robert L. Goldenberg, and Sten H. Vermund are with the Center for Research in Women's Health, University of Alabama at Birmingham. Moses Sinkala is with the Lusaka District Health Board, Zambian Ministry of Health, Lusaka.), Sten H Vermund (0000-0001-7289-8698, Jeffrey S. A. Stringer is with the Center for Research in Women's Health, University of Alabama at Birmingham, and the Center for Infectious Disease Research in Zambia, Lusaka, Zambia. Dwight J. Rouse, Robert L. Goldenberg, and Sten H. Vermund are with the Center for Research in Women's Health, University of Alabama at Birmingham. Moses Sinkala is with the Lusaka District Health Board, Zambian Ministry of Health, Lusaka.)
Ano2002
Volume92
Fascículo3
Páginas365-366
Data de publicação2002-03-01
Peer ReviewedSim
Open AccessNão
TipoARTICLE
PeriódicoAmerican Journal of Public Health (JOURNAL)
Identificadores do periódicoISSN: 0090-0036 • E-ISSN: 1541-0048
EditoraAmerican Public Health Association (PUBLISHER • US)
DOI10.2105/ajph.92.3.365
PMID11867311
OpenAlexW2151211179
IdiomaEN
Referências citadas8

Objectives. This study evaluated the validity of concerns about the toxicity of nevirapine (NVP) that have delayed its implementation as a perinatal HIV prevention strategy. Methods. A decision analysis model compared 3 strategies: single-dose NVP, short-course zidovudine (ZDV), and no intervention. Results. NVP would prevent more deaths than ZDV and no intervention as long as the rate of NVP toxicity did not exceed, respectively, 9 times that observed in the earlier NVP clinical trial and 42 times that observed in the clinical trial. NVP would be economically preferable to ZDV as long as the rate of toxicity did not exceed 22 times that observed in the clinical trial. Conclusions. Field implementation of NVP should not be delayed by concerns about its toxicity. (Am J Public Health. 2002;92:365–366)

Antiretroviral therapy · Environmental health · Family medicine · Human immunodeficiency virus (HIV) · Nevirapine · Toxicity · Biological Research and Disease Studies · HIV/AIDS drug development and treatment · HIV/AIDS Research and Interventions · Internal Medicine · Medicine · Pediatrics